CMEtracker Log in | Veritas Institute for Medical Education, Inc. | Saturday, December 27, 2014


American Association for Geriatric Psychiatry's 2010 Annual Meeting
A MILE IN MY SHOES: Finding Comprehensive Solutions to the Problems of Aging
Sunday, March 7, 2010
Savannah, Georgia


Not Just "Normal Aging": Managing Depression and Anxiety in the Geriatric Population

Supported by an educational grant from Forest Research Institute, Inc., a wholly-owned subsidiary of Forest Laboratories, Inc.
Provided by the American Association for Geriatric Psychiatry
Facilitated by Veritas Institute for Medical Education, Inc.

Important: Participants who attended the live activity during AAGP's 2010 Annual Meeting may not request credit for viewing the Webcast.



To successfully earn credit, participants must complete the activity online during the valid credit period that is noted below.


Follow these steps to earn CME credit:

  1. Review the target audience, learning objectives, overview, and disclosures.
  2. Participate in the educational Webcast.
  3. Complete the evaluation and posttest questions.

There are no fees for participating in or receiving credit for this online educational activity.


Target Audience

This activity is designed for psychiatrists, geriatric psychiatrists, advanced practice nurses, and other health care professionals interested in the diagnosis, treatment, and management of depression and anxiety in geriatric patients.


Learning Objectives

  • Identify and evaluate the dimensions of geriatric depression and/or anxiety, using measurement-based principles
  • Individualize a stepwise pharmacologic treatment plan for geriatric patients suffering from depression and/or anxiety, based on responsiveness and tolerability, within a care management context
  • Implement psychosocial interventions, in collaboration with other medical and mental health practitioners


Overview

Depression and anxiety, which are extremely common in the geriatric population, have only recently begun to garner serious attention. These conditions diminish quality of life and cause increased morbidity, disability, and death, from both natural causes and suicide. Unfortunately, many health care practitioners mistakenly believe that depression and anxiety are part of normal aging, and are thus unable to identify these disorders in the presence of dementia and other neurological or medical conditions. Even when health care professionals recognize depression and anxiety in their elderly patients, they often undertreat or incorrectly treat these conditions, with overreliance on benzodiazepines and underuse of antidepressants.

To reduce the morbidity and mortality associated with depression and anxiety, health care professionals who treat the elderly need education to improve the identification and diagnosis of these conditions, using measurement-based principles that particularly focus on the clinical interview and assessment tools. They also need to learn how to optimally treat these disorders with both pharmacologic agents and psychosocial interventions, assessing for side effects and making treatment changes as necessary. This Webcast provides health care professionals with the information they need to properly recognize and treat depression and anxiety in their elderly patients.


Accreditation Statement

The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Geriatric Psychiatry designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Acknowledgment
This activity is provided by the American Association for Geriatric Psychiatry and facilitated by Veritas Institute for Medical Education, Inc. and supported by an educational grant from Forest Research Institute, Inc., a wholly-owned subsidiary of Forest Laboratories, Inc. Activity content was developed independently by the faculty. The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of the sponsor or commercial supporter.

Release Date:   07/30/2010
Expiration Date:   07/31/2011

The AAGP owns the copyright for this material or has obtained permission to distribute this material from all speakers.

If you have questions or would like additional information, please contact main@aagponline.org, or Marjorie Vanderbilt at mvanderbilt@aagponline.org.

AAGP’s Policy on Privacy and Confidentiality



Disclosures


Faculty Disclosure Statement
CME-certified activities must be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, faculty are required to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the educational activity. Any relationships faculty members may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.


Charles F. Reynolds, III, MD—Bristol-Myers Squibb (grant/research support); Forest Laboratories, Inc. (grant/research support); Eli Lilly and Company (grant/research support); National Institute of Mental Health (grant/research support); National Institute on Aging (grant/research support); National Center for Minority Health and Health Disparities (grant/research support); Pfizer Inc (grant/research support); Wyeth (grant/research support); National Heart, Lung and Blood Institute (grant/research support); John A. Hartford Foundation (grant/research support); American Foundation for Suicide Prevention (grant/research support); Commonwealth of Pennsylvania (grant/research support); UPMC endowment in geriatric psychiatry (grant/research support)

George S. Alexopoulos, MD—AstraZeneca (speakers bureau); Bristol-Myers Squibb (speakers bureau); Cephalon Inc (grant/research support); Forest Laboratories, Inc. (consultant/advisor, speakers bureau, grant/research support); Janssen (speakers bureau); Johnson & Johnson (stockholder); Eli Lilly and Company (speakers bureau); Pfizer Inc (speakers bureau); Sanofi-Aventis (consultant/advisor)

Joel E. Streim, MD—National Institute for Mental Health (grant/research support); VAHSR&D (grant/research support); Health Resources and Services Administration (grant/research support); National Institute on Aging (grant/research support)

Julie Wetherell, PhD—Forest Laboratories, Inc. (grant/research support); National Institute of Mental Health (grant/research support); US Veterans Health Administration (grant/research support)

The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.


Copyright © 2010 Veritas Institute for Medical Education, Inc. All rights reserved.